Oral drug for non-small cell lung cancer launched

摘要

Tarceva (erlotinib),a new oral drug to treat non-small cell lung cancer,has been launched by Abbott.Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor,which is licensed for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.